Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLOLIPID vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Flolipid (simvastatin) is a competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Reduction of elevated total-C, LDL-C, Apo B, and TG and to increase HDL-C in patients with primary hyperlipidemia (Fredrickson type IIa and IIb) or mixed dyslipidemia,Reduction of elevated TG in patients with hypertriglyceridemia (Fredrickson type IV),Treatment of primary dysbetalipoproteinemia (Fredrickson type III) when diet is not sufficient,Reduction of total-C and LDL-C in patients with homozygous familial hypercholesterolemia,Prevention of cardiovascular events in patients with high risk of coronary heart disease
Mild to moderate pain,Pain accompanied by fever
Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life is approximately 3 to 4 hours; however, due to extensive enterohepatic recirculation, the clinical duration of action is longer, allowing for once-daily dosing.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Simvastatin is a prodrug; the lactone ring is hydrolyzed in vivo to the active β-hydroxyacid form. It is extensively metabolized by CYP3A4 and also undergoes glucuronidation. Major metabolites include the active β-hydroxyacid and 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Primarily hepatic metabolism with biliary excretion; approximately 90% of the dose is recovered in feces, and less than 10% in urine, mainly as metabolites.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
More than 99% bound, primarily to albumin.
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Approximately 0.4 L/kg, indicating distribution into extravascular tissues; not extensively bound to tissues.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Oral bioavailability is not applicable as Flolipid is an intravenous lipid emulsion; bioavailability is 100% via intravenous route.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
For GFR 30 to <60 m L/min/1.73 m²: maximum dose 2 mg once daily. For GFR <30 m L/min/1.73 m²: not recommended.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. No specific Child-Pugh-based dosing adjustments provided; use with caution in mild hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
For patients 8 years and older with heterozygous familial hypercholesterolemia: 2 mg orally once daily; may increase to 4 mg once daily after 4 weeks.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
No dose adjustment required; monitor for increased risk of myopathy and renal function in patients over 65 years.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
Simvastatin is contraindicated for use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone) and with gemfibrozil, cyclosporine, or danazol. Do not exceed 20 mg simvastatin daily with amiodarone, amlodipine, or ranolazine. Do not exceed 40 mg simvastatin daily with lomitapide or diltiazem. Avoid grapefruit juice. Increased risk of myopathy/rhabdomyolysis with these drugs.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Myopathy/Rhabdomyolysis: Risk factors include age >65 years, female, renal impairment, uncontrolled hypothyroidism, and concomitant use of certain drugs (see Black Box Warning).,Hepatic effects: Persistent elevations in serum transaminases; recommend liver enzyme monitoring before and during treatment.,Increased risk of diabetes mellitus: Small increase in fasting glucose and Hb A1c.,Interstitial lung disease: Rare cases reported.,Use with caution in patients with predisposing factors for renal impairment.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Hypersensitivity to any component of Flolipid,Active liver disease or unexplained persistent elevations of serum transaminases,Concomitant use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone),Concomitant use of gemfibrozil, cyclosporine, or danazol,Pregnancy and breastfeeding,Women of childbearing potential unless using effective contraception
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Grapefruit juice may modestly increase pitavastatin exposure; limit to small amounts (≤8 oz per day). No other significant food interactions; can be taken with or without food. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
FLOLIPID (rosuvastatin) is contraindicated in pregnancy. First trimester: Limited human data show no increased risk of major congenital anomalies, but animal studies show embryotoxicity. Second and third trimesters: Statins may reduce fetal cholesterol synthesis; risk of fetal harm cannot be excluded. Use only if pregnancy risk accepted.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Breastfeeding is contraindicated during rosuvastatin therapy. M/P ratio: unknown. Rosuvastatin is excreted in rat milk; human data absent. Potential for serious adverse reactions in nursing infants.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
FLOLIPID should be discontinued upon pregnancy detection. No dose adjustments in pregnancy as use is contraindicated. Pharmacokinetic changes in pregnancy may reduce rosuvastatin exposure, but safety data insufficient to recommend resuming.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Flolipid (pitavastatin) is a potent statin with minimal CYP metabolism, reducing drug interactions; monitor for myopathy and hepatotoxicity; avoid in active liver disease; dose adjustment needed with renal impairment (Cr Cl <30 m L/min); no significant food effect, but grapefruit juice may modestly increase exposure; consider in patients with statin intolerance due to fewer CYP-mediated interactions.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Take Flolipid at the same time each day, with or without food.,Avoid consuming large amounts of grapefruit juice; a small glass (8 oz) is acceptable.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you develop jaundice, dark urine, or abdominal pain (signs of liver problems).,Continue a heart-healthy diet and exercise while taking this medication.,Do not double the dose if you miss one; take the next dose at the usual time.,Inform your doctor of all other medications, including over-the-counter drugs and supplements.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLOLIPID vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
FLOLIPID is a HMG-CoA Reductase Inhibitor (Statin) that works by Flolipid (simvastatin) is a competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. This reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from plasma.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLOLIPID and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLOLIPID is: Flolipid (pitavastatin) 2 mg orally once daily; may increase to 4 mg once daily based on response; maximum dose 4 mg/day.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLOLIPID and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLOLIPID is classified as Category C. FLOLIPID (rosuvastatin) is contraindicated in pregnancy. First trimester: Limited human data show no increased risk of major congenital anomalies, but animal studies show embryotox. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.